Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

47 та иш

Иш: Personalized rosuvastatin therapy in problem patients with partial statin intolerance

  1. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

    Colin Baigent, Anthony Keech, Patricia M. Kearney +8

    Шарҳ мақола20056 иқтибос
    ABI

  2. <i>SLCO1B1</i> Variants and Statin-Induced Myopathy — A Genomewide Study

    The SEARCH Collaborative Group

    Мақола20083 иқтибос
    ABI

  3. Lipid-lowering response to statins is affected by CYP3A5 polymorphism

    Kari T. Kivistö, Mikko Niemi, Elke Schaeffeler +6

    Мақола20043 иқтибос
    ABI

  4. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects

    William E. Evans, Howard L. McLeod

    Мақола20033 иқтибос
    ABI

  5. Effect of Polymorphic <i>CYP3A5</i> Genotype on the Single‐Dose Simvastatin Pharmacokinetics in Healthy Subjects

    Kyoung‐Ah Kim, Pil‐Whan Park, Ock‐Je Lee +2

    Мақола20063 иқтибос
    ABI

  6. Comprehensive efforts to increase adherence to statin therapy

    Alexander Vonbank, Stefan Agewall, Keld Per Kjeldsen +13

    Мақола20163 иқтибос
    ABI

  7. <i>CYP3AP1*3</i>Allele Is Associated With Lipid-Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women

    Yanpeng Li, Lirong Zhang, Min Jia +1

    Мақола20102 иқтибос
    ABI

  8. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

    Marilu Fiegenbaum, F DASILVEIRA, C VANDERSAND +4

    Мақола20052 иқтибос
    ABI

  9. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

    Paul Martin, Mike J. Warwick, Aaron Dane +4

    Мақола20032 иқтибос
    ABI

  10. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

    Joseph P. Kitzmiller, Jasmine A. Luzum, Damiano Baldassarre +2

    Мақола20142 иқтибос
    ABI

  11. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

    Laure Elens, Matthijs L. Becker, Vincent Haufroid +5

    Мақола20112 иқтибос
    ABI

  12. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity

    Fumihiro Sata

    Мақола20002 иқтибос
    ABI

  13. Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients

    Patricia D. Maningat, Jan L. Breslow

    Мақола20112 иқтибос
    ABI

  14. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

    Daqing Wang, Yingying Guo, Steven Wrighton +2

    Мақола20102 иқтибос
    ABI

  15. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

    Erik S.G. Stroes, Paul D. Thompson, Alberto Corsini +37

    Шарҳ мақола20152 иқтибос
    ABI

  16. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

    Marja K. Pasanen, Mikko Neuvonen, Pertti J. Neuvonen +1

    Мақола20062 иқтибос
    ABI

  17. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  18. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  19. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  20. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  21. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  22. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  23. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  24. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  25. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI